Markt geschlossen· · HKD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, in children with achondroplasia (ACH). In the first and lowest dose cohort of 0.064mg/kg QD, children aged 6 years and older with ACH who received lavengratinib for 27 weeks achieved a mean increase of
Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused on expanding its pipeline through external R&D partnerships. The company has transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics, adjusting its approach in that market. Eli Lilly has become closely associated with obesity and diabetes treatments, but this latest update shows the company putting more emphasis on partnerships and regional focus. The Abbisko...
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC). As a multicenter, open-label Phase I/II clinical study, the combination will evaluate the safety and efficacy of Abbisko's first-in-class oral small-molecule PD-L1 inhibitor, lu
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.